sur NICOX (EPA:COX)
Nicox Announces Financial Stability Extension
Nicox SA has announced an extended cash runway, ensuring the funding of current operations beyond Q1 2028. As of August 31, 2026, the company reported €8.4 million in cash, a significant increase from December 2025. The anticipated U.S. NDA approval milestone for NCX 470 could extend financial viability into 2029, supplemented by potential royalties post-launch in the latter half of 2027.
The company continues to explore strategic growth opportunities, including potential collaborations. Nicox remains focused on cost management and resource optimization to support its strategic goals. A shareholder loan option from Vester Finance remains available, providing additional financial flexibility.
In management changes, Doug Hubatsch transitions to Chief Scientific Advisor, while Siobhan Garbutt takes over clinical development leadership, enhancing Nicox's capability to navigate future growth opportunities.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NICOX